今年的ASCO大会主题为“Same Great Science，New Virtual Format(科学依然博大精深，新虚拟格局蓄势待发)”。在这个特定的非常时期，ASCO将依然致力于呈现更多重要研究发现和临床数据成果，以此平台与来自世界各地的肿瘤学者及研究者分享肿瘤领域内最新的学术成果和更优化的诊疗方案。

同时，来自我国多个顶尖肿瘤医学团队针对特瑞普利单抗治疗的有效性与安全性的研究结果的更新也如约而至。这也是君实生物连续第3年在国际性权威会议上汇报特瑞普利单抗的研究进展。

Overall survival and biomarker analysis of a phase Ib combination study of Toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

一项探索特瑞普利单抗联合阿昔替尼治疗转移性黏膜黑色素瘤患者的Ib期临床研究的总生存期和生物标志物分析

Abstract #10007

汇报板块：Oral abstract session

Recombinant humanized anti-PD-1 monoclonal antibody toripalimab in patients with metastatic urothelial carcinoma: results of an open-label phase II clinical study POLARIS-03.

特瑞普利单抗治疗转移性尿路上皮癌患者：一项开放性II期临床研究POLARIS-03的研究结果

Abstract #5040

汇报板块：Poster Session #109

Clinical response and biomarker analysis of POLARIS-02 a Phase II study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with metastatic nasopharyngeal carcinoma.

一项探索特瑞普利单抗治疗转移性鼻咽癌患者的II期临床研究POLARIS-02的临床应答及生物标志物分析

Abstract #6542

汇报板块：Poster Session #203

An exploratory study of sorafenib plus toripalimab for unresectable hepatocellular carcinoma with portal vein tumor thrombus.

一项索拉非尼联合特瑞普利单抗治疗不可切除肝细胞癌合并门静脉癌栓患者的探索性研究

Abstract #TPS4658

汇报板块：Poster Session #266

A phase II study of vorolanib (CM082) in combination with toripalimab (JS001) in patients with advanced mucosal melanoma.

一项vorolanib(CM082)联合特瑞普利单抗治疗晚期黏膜黑色素瘤患者的II期研究

Abstract #10040

汇报板块：Poster Session #389

Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors.

一项探索特瑞普利单抗联合标准化疗一线治疗实体瘤患者的II期篮式研究的临床应答和生物标志物分析

Abstract #e15083

汇报板块：Publication Only

Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: Real-world data from a single center.

肝动脉灌注化疗联合阿帕替尼和特瑞普利单抗治疗晚期肝细胞癌：来自单中心的真实世界数据

Abstract #e16602

汇报板块：Publication Only

Combined recombinant humanized anti-PD-1 monoclonal antibody (JS001) and nab-paclitaxel/gemcitabine (AG) as the first-line therapy for patients with advanced pancreatic adenocarcinoma: Preliminary results of an open-label, phase Ib/II clinical study.

重组人源化抗PD-1单克隆抗体(JS001)联合白蛋白紫杉醇/吉西他滨(AG)作为晚期胰腺腺癌患者的一线治疗：一项开放标签、Ib / II期临床研究的初步结果

Abstract #e16792

汇报板块：Publication Only

A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

一项探索特瑞普利单抗联合化疗治疗EGFR-TKI治疗失败的EGFR突变的晚期NSCLC患者的多中心、Ⅱ期研究的疗效和生物标志物分析

Abstract #e21618

汇报板块：Publication Only

关于特瑞普利单抗

国家药监局(NMPA)已受理特瑞普利单抗(商品名为拓益)用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌(NPC)患者的新适应症上市申请，这也是全球首个抗PD-1单抗治疗复发/转移性鼻咽癌的新药上市申请。

2020年美国癌症研究协会(AACR)年会由线下转为线上，于4月27日-28日和6月22日-24日分两次举办。会议期间，北京大学肿瘤医院陆明教授代表其研究团队公布了和黄医药自主研发的口服酪氨酸激酶抑制剂(TKI)索凡替尼(surufatinib)联合特瑞普利单抗(toripalimab，针对PD-1的人源化lgG4型单克隆抗体)治疗晚期实体瘤的Ⅰ期临床研究结果(Abstract # 9563)。